Compare Fox Corp Class A (FOXA) vs Novavax Inc (NVAX) Price & Performance

Fox Corporation (FOXA) trades at $62.68, down slightly by 0.03% on the day. The stock shows a bullish technical signal with strong earnings beats in recent quarters, including Q2 2026 EPS of $1.79 versus $1.44 expected. Revenue grew to $16.30 billion in 2025, with a net income margin of 13.88%. Key developments include the pending $22 billion acquisition of Roku, which is under DOJ review, and a dividend payment scheduled for September 2026.

The outlook is positive with a consensus price target of $72.00, implying 15% upside. Strengths include robust cash flow and analyst support, but risks involve regulatory scrutiny of the Roku deal and a projected decline in 2026 net income. The stock presents a value opportunity with a P/E of 16.55, though investors should monitor deal progression and earnings sustainability.

Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.

The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.